Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells
more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with
cyclosporine works in treating older patients with relapsed acute myeloid leukemia.